Lifileucel Induces Response in Metastatic Melanoma Independent of Number of IL-2 Doses Received
Source: OncLive, December 2022
Lifileucel (LN-44) achieved safety and efficacy irrespective of the number of aldesleukin (IL-2) doses administered to patients with advanced melanoma, according to data from a post-hoc analysis of the phase 2 C-144-01 trial (NCT02360579) presented at the 2022 ESMO Immuno-Oncology Annual Congress.
In the overall population (n = 153), the objective response rate (ORR) for patients who received up to 6 doses of IL-2 following lifileucel was 31.4% (95% CI, 24.1%-39.4%) by RECIST v1.1 criteria and independent review committee (IRC) assessment. Those who received 1 to 2 doses of IL-2 had a slightly higher ORR of 37.5% (95% CI, 15.2%-64.6%) vs those who received 3 to 4 doses (30.8%; 95% CI, 14.3%-51.8%) or 5 to 6 doses (31.2%; 95% CI, 22.7%-40.8%). However, there was no significant difference in ORR associated with the number of IL-2 doses received (P = .87).